3-(2,4-Dihydroxyphenyl)-5-hydroxy-7-methoxy-4H-1-benzopyran-4-one
3-(2,4-Dihydroxyphenyl)-5-hydroxy-7-methoxy-4H-1-benzopyran-4-one Basic information
- Product Name:
- 3-(2,4-Dihydroxyphenyl)-5-hydroxy-7-methoxy-4H-1-benzopyran-4-one
- Synonyms:
-
- 3-(2,4-Dihydroxyphenyl)-5-hydroxy-7-methoxy-4H-1-benzopyran-4-one
- Cajanin
- 2',4',5-Trihydroxy-7-methoxyisoflavone
- 4H-1-Benzopyran-4-one, 3-(2,4-dihydroxyphenyl)-5-hydroxy-7-methoxy-
- CAS:
- 32884-36-9
- MF:
- C16H12O6
- MW:
- 300.26
- EINECS:
- 628-471-3
- Mol File:
- 32884-36-9.mol
3-(2,4-Dihydroxyphenyl)-5-hydroxy-7-methoxy-4H-1-benzopyran-4-one Chemical Properties
- Melting point:
- 208-210 °C(Solv: acetone (67-64-1))
- Boiling point:
- 605.5±55.0 °C(Predicted)
- Density
- 1.512±0.06 g/cm3(Predicted)
- pka
- 6.19±0.20(Predicted)
- form
- Solid
- color
- Off-white to light yellow
3-(2,4-Dihydroxyphenyl)-5-hydroxy-7-methoxy-4H-1-benzopyran-4-one Usage And Synthesis
Uses
Cajanin is a potent and orally active anti-melanogenic agent. Cajanin shows antiproliferative activity in MNT1 Cells. Cajanin efficiently decreases the melanin content. Cajanin down-regulates the mRNA and protein expression levels of MITF, tyrosinase, TRP-1 and Dct (TRP-2). Cajanin induces cell cycle arrest at G2/M and S phase. Cajanin stimulates osteoblast proliferation. Cajanin has the potential for the research of human hyperpigmented disorders and menopausal osteoporosis[1][2].
Definition
ChEBI: Cajanin is a member of 7-methoxyisoflavones. It has a role as a metabolite.
in vivo
Cajanin (10 mg/kg, p.o.; daily for 30 consecutive days) increases the BMD levels in all anatomical regions of the skeleton studied in Sprague Dawley rats[1].
References
[1] Netcharoensirisuk P, et al. Cajanin Suppresses Melanin Synthesis through Modulating MITF in Human Melanin-Producing Cells. Molecules. 2021 Oct 5;26(19):6040. DOI:10.3390/molecules26196040
[2] Bhargavan B, et al. Methoxylated isoflavones, cajanin and isoformononetin, have non-estrogenic bone forming effect via differential mitogen activated protein kinase (MAPK) signaling. J Cell Biochem. 2009 Oct 1;108(2):388-99. DOI:10.1002/jcb.22264
[3] Wensaas AJ, et al. Fatty acid incubation of myotubes from humans with type 2 diabetes leads to enhanced release of beta-oxidation products because of impaired fatty acid oxidation: effects of tetradecylthioacetic acid and eicosapentaenoic acid. Diabetes. 2009 Mar;58(3):527-35. DOI:10.2337/db08-1043
3-(2,4-Dihydroxyphenyl)-5-hydroxy-7-methoxy-4H-1-benzopyran-4-oneSupplier
- Tel
- +86-21-20908456
- sales@BioChemBest.com
- Tel
- 0871-65217109 13211707573;
- y.liu@mail.biobiopha.com
- Tel
- 0510-85629785 18013409632
- sales@reading-chemicals.com
- Tel
- 702-983-3769
- sales@albtechnology.com
- Tel
- 18607101326 15172504745
- aileen@chemfaces.com